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The multisubunit Mediator complex of Saccharomyces cerevisiae is required for most RNA polymerase II (Pol
II) transcription. The Mediator complex is composed of two subcomplexes, the Rgr1 and Srb4 subcomplexes,
which appear to function in the reception of activator signals and the subsequent modulation of Pol II activity,
respectively. In order to determine the precise composition of the Mediator complex and to explore the specific
role of each Mediator protein, our goal was to identify all of the Mediator components. To this end, we cloned
three previously unidentified Mediator subunits, Med9/Cse2, Med10/Nut2, and Med11, and isolated mutant
forms of each of them to analyze their transcriptional defects. Differential display and Northern analyses of
mRNAs from wild-type and Mediator mutant cells demonstrated an activator-specific requirement for each
Mediator subunit. Med9/Cse2 and Med10/Nut2 were required, respectively, for Bas1/Bas2- and Gcn4-mediated
transcription of amino acid biosynthetic genes. Gal11 was required for Gal4- and Rap1-mediated transcrip-
tional activation. Med11 was also required specifically for MFa1 transcription. On the other hand, Med6 was
required for all of these transcriptional activation processes. These results suggest that distinct Mediator
proteins in the Rgr1 subcomplex are required for activator-specific transcriptional activation and that the ac-
tivation signals mediated by these Mediator proteins converge on Med6 (or the Srb4 subcomplex) to modulate
Pol II activity.
Regulation of mRNA synthesis by transcriptional activator
proteins requires many diverse regulatory proteins collectively
called transcriptional coactivators (for reviews, see references
2, 17, and 40). The TATA binding protein-associated factors
(TAFIIs), which compose the TFIID complex, and the multi-
subunit Mediator complex are the two major coactivators that
enable the basal transcription machinery to respond to gene-
specific transcriptional regulatory proteins.
TAFIIs were initially identified in human and Drosophila as
essential factors for transcriptional activation in a reconsti-
tuted transcription system (12, 33). Biochemical analysis of
TFIID revealed a modular structure in which a large TAFII
subunit, acting as a scaffold, binds to several distinct TAFII
subunits, each of which interacts with specific transcriptional
activator proteins (4). However, depletion or inactivation of
TAFIIs from the yeast Saccharomyces cerevisiae caused no ob-
vious defect in transcriptional activation in vivo (28, 41).
Therefore, it was proposed that TAFIIs function as essential
cofactors for transcription of only a subset of genes, rather
than as general targets of transcriptional activators (1, 35).
In contrast to the limited requirement for TAFIIs, a second
coactivator complex, the Mediator complex, appears to be re-
quired for the transcription of most RNA polymerase II (Pol
II)-transcribed genes. The Mediator complex is required not
only for transcriptional activation but also for the stimulation
of basal transcription and higher carboxy-terminal domain
(CTD) phosphorylation efficiency by TFIIH (18). Mediator is
tightly associated with the CTD of Pol II and is composed of
the Med proteins (24, 29); Gal11, Rgr1, Sin4, Hrs1, and Rox3
(9, 18, 26, 39); and the Srb family of proteins. Mediator com-
ponents with genetically similar phenotypes are physically as-
sociated, thus forming two major Mediator subcomplexes, the
Srb4 subcomplex and the Rgr1 subcomplex (23). The Srb4
subcomplex contains all of the genetically dominant Srb pro-
teins (Srb2, -4, -5, and -6) and Med6 and appears to modulate
Pol II activity through its interaction with the CTD. The Srb4
subcomplex was successfully reconstituted in vitro with recom-
binant Med6 and Srb proteins (19), and the functional inter-
actions between components of this subcomplex were shown
genetically by the suppressor relationships among the SRB4,
SRB6, and MED6 genes (22, 23).
The remaining Mediator components form the Rgr1 sub-
complex, which plays an apparent role in activator-specific
functions. At least one activator-specific module, the Gal11
module, which contains Gal11, Sin4, and Hrs1, was shown to
interact physically with the C-terminal domain of the Rgr1
protein. Mutations in each of the components of the Gal11
module were shown to yield similar mutant phenotypes and to
affect transcriptional regulation of the same subset of genes
(15, 26, 32, 37). These results suggest that the Gal11 module
functions in the receiving end of signals from a subset of
gene-specific transcriptional regulators. Other members of the
Rgr1 subcomplex interact with Rgr1 through regions other
than its C-terminal domain (23). However, whether these
polypeptides form a module(s) with a specific regulatory func-
* Corresponding author. Mailing address: Center for Molecular
Medicine, Samsung Biomedical Research Institute, Sungkyunkwan
University College of Medicine, 50 IIwon-dong, Kangnam-ku, Seoul
135-230, Korea. Phone: 82-2-3410-3638. Fax: 82-2-3410-3649. E-mail:
yjkim@smc.samsung.co.kr.
† Present address: Center for Ligand and Transcription, Chonnam
National University, Kwangju 500-757, Korea.
‡ Present address: Department of Parasitology, College of Medi-
cine, Yonsei University, Seoul 120-752, Korea.
979
 o
n
 January 2, 2020 at Yonsei Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
tion as do the Gal11 module components remains to be exam-
ined.
In order to elucidate the mechanism by which Mediator
functions to bridge gene-specific activators and Pol II, it is
important to address how activator specificity is achieved and
to decipher which Mediator proteins are required for specific
transcriptional activation events. Despite the fact that a num-
ber of new Mediator genes have been reported recently (29),
the precise composition of the Mediator complex remains elu-
sive. Therefore, we purified the Mediator complex to homo-
geneity from S. cerevisiae with the use of an anti-Rgr1 antibody
column and thus were able to identify all of the remaining
Mediator proteins (Med9/Cse2, Med10/Nut2, and Med11) that
had escaped earlier identification efforts. Here we report the
functional analysis of these new Mediator genes and present
evidence that defines the activator-specific requirements of in-
dividual Mediator proteins tethered to Rgr1. Our results reveal
the specific functions of each Mediator component in the relay
of gene-specific activator signals to Pol II.
MATERIALS AND METHODS
Protein purification. A whole-cell extract from a strain containing His-tagged
Med6 was fractionated according to the procedure described by Kim et al. (18)
with the following modifications. We employed an immunoaffinity purification
step with the use of an antibody to Rgr1 in order to remove all of the contam-
inating polypeptides that copurified with holopolymerase through the preceding
chromatographic steps. Anti-Rgr1 antiserum (1 ml) was conjugated with protein
G-agarose beads (1 ml) (GIBCO BRL, Gaithersburg, Md.), and the resulting
affinity resin was used to purify holopolymerase from 2 ml of the MonoQ fraction
(protein concentration, 0.6 mg/ml) according to the procedure described by Lee
and Kim (23). After separation of the affinity column-eluted proteins on a
sodium dodecyl sulfate (SDS)-polyacrylamide (13%) gel, proteins were stained
with Coomassie blue, and previously unidentified low-molecular-size Mediator
proteins (15, 19, and 20 kDa) were excised for peptide sequencing.
Peptide sequencing by ion trap MS. The excised protein bands were subjected
to in-gel reduction, S-carboxyamidomethylation, and tryptic digestion (Promega,
Madison, Wis.), and a 10% aliquot of the resultant mixture was analyzed as
follows. Sequence information was determined by capillary (180-mm by 15-cm
column; LC Packings, Amsterdam, The Netherlands) reverse-phase chromatog-
raphy coupled to the electrospray ionization source of a quadrupole ion trap
mass spectrometer (Finnigan LCQ, San Jose, Calif.) (30). Peptides were eluted
with a gradient of 10.8 to 41.6% acetonitrile in 0.1% acetic acid–0.02% triflu-
oroacetic acid. The instrument was programmed to acquire successive sets of
three scan modes consisting of full-scan mass spectrometry (MS) over the m/z
range of 395 to 1,118 m, followed by two data-dependent scans on the most
abundant ion in that full scan. These data-dependent scans allowed the auto-
matic acquisition of a high-resolution (zoom scan) spectra to determine charge
state and exact mass and of MS-MS spectra for the peptide sequence informa-
tion. Intepretation of the resulting MS-MS spectra of the peptides was facilitated
by searching the National Center for Biotechnology Information nr and dbest
databases with the algorithm Sequest (7), followed by manual inspection.
Cloning and disruption of Mediator genes. The flanking regions of MED9 (bp
2239 to 13 and 1277 to 1559), MED10 (2438 to 254 and 1203 to 1623), and
MED11 (2473 to 2138 and 1519 to 1851) (the translation initiation site is 11)
were amplified from yeast genomic DNA by PCR. Each pair of amplified 59
upstream and 39 downstream regions was cloned into the BamHI and HindIII
sites of pRS316 to construct the gap repair plasmids pSJ1 (MED9), pSJ2
(MED10), and pSJ3 (MED11). In order to construct gene disruption plasmids,
TRP1 was introduced into the EcoRI site between the cloned 59 and 39 regions
of the Mediator genes on these gap repair plasmids to yield pSJ1-1, pSJ2-1, and
pSJ3-1. Wild-type alleles of the Mediator genes were cloned with the use of the
pSJ1, -2, and -3 gap repair plasmids as described by Lee et al. (24). Sequencing
analysis of the recovered inserts confirmed the isolation of wild-type alleles of
MED9, MED10, and MED11 on pSJ4, -5, and -6, respectively. Mediator gene
deletion strains were made according to the procedure described by Lee et al.
(24) with the use of the gene disruption plasmids to yield strains YSJ9M, YSJ10S,
and YSJ11S (Table 1).
Isolation of ts mutants. The temperature-sensitive (ts) mutants for MED10
and MED11 were generated according to the procedure described by Lee et al.
(24) with the following modifications. The MED10 and MED11 mutant PCR
products were cotransformed into YSJ10S and YSJ11S, respectively, with a
linearized, HIS3-based pSJ7 or pSJ8 plasmid containing 250 bp of flanking
sequences from the corresponding MED genes at their termini. Transformants
were selected against 5-fluoro-orotic acid to remove the corresponding wild-type
MED gene. The 5-fluoro-orotic acid-resistant colonies were grown on yeast
extract-peptone-dextrose (YPD) medium, and mutants showing ts lethality were
isolated.
Antibody preparation and immunoprecipitation experiments. MED9 and
MED11 open reading frames (ORFs) were inserted into the BamHI and XhoI
sites of the pGEX-4T-1 vector (Pharmacia, Uppsala, Sweden) to construct the
glutathione S-transferase (GST)–Med9 and glutathione S-transferase–Med11
fusion protein expression constructs, respectively. Polyclonal antibodies to the
fusion proteins were raised in rats and affinity purified as described by Lee et al.
(24). Instead of raising antibodies to Med10, we introduced a double hemagglu-
tinin (HA) tag at the N-terminal end of Med10 by PCR with primers that
contained two copies of the HA epitope sequence (p10HA-2 [59-ATC CAT ATG
ATG TTC CAG ATT ATG C-39] and p10HA-3 [59-GTC AGG TAC GTC GTA
AGG GTA AGC ATA ATC TGG-39]) and cloned the resulting PCR product
into the BamHI and HindIII sites of pRS315 to make pSJ9. The wild-type copy
of the MED10 gene on pRS316 in strain YSJ10S was replaced with pSJ9 to make
a strain (YSJ10HA) that contained only the HA-tagged version of Med10.
Immunoprecipitation experiments were performed as described by Lee and Kim
(23).
TABLE 1. Yeast strains used in this study
Strain Genotype
YPH500..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1
YPHBAS................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1, p2100a (HIS3), pSH18-34b (URA3)
YPHG4 ..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1, pHYC1 (66)c (URA3)
YSJ9M....................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed9::TRP1
YSJ9R ....................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed9::TRP1/MED9 on pRS316 (URA3)
YSJ9BAS ...............................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed9::TRP1, p2100 (HIS3), pSH18-34 (URA3)
YSJ9G4 ..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed9::TRP1, pHYC1 (66) (URA3)
YSJ10S ...................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/MED10 on pRR316 (URA3)
YSJ10M..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/ts mutant med10 on pRS313 (HIS3)
YSJ10R ..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/ts mutant med10 on pRS313 (HIS3)/
MED10 on pRS316 (URA3)
YSJ10HA...............................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/HA-MED10 on pRR315 (LEU2)
YSJ10BAS .............................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/ts mutant med10 on pRS315 (LUE2),
p2100 (HIS3), pSH18-34 (URA3)
YSJ10G4 ................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed10::TRP1/ts mutant med10 on pRS315 (LUE2),
pHYC1 (66) (URA3)
YSJ11S ...................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed11::TRP1/MED11 on pRR316 (URA3)
YSJ11M..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed11::TRP1/med11 ts mutation on pRS313 (HIS3)
YSJ11R ..................................MATa ade2-101 ura3-52 lys2-801 trp1-D63 his3-D200 leu2-D1 Dmed11::TRP1/med11 ts mutation on pRS313 (HIS3)/
MED11 on pRS316 (URA3)
a p2100, full-length lexA-BAS2 fusion; 2mm HIS3 (43).
b pSH18-34, lexAop-lacZ reporter; 2mm URA3 (43).
c pHYC1 (66), Gcn4 binding site-lacZ reporter; 2mm URA3 (11).
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Differential display of Mediator mutant mRNAs. Wild-type and mutant yeast
cells were grown on YP-glucose medium to early exponential phase at 30°C (A600
5 0.3 to 0.4) and were then allowed to grow for an additional 2.5 h at 37°C. The
cells were then harvested, and poly(A)1 RNA was prepared. Both the wild-type
and mutant poly(A)1 RNAs were converted into cDNAs with nine two-base-
anchored oligo(dT) primers (T1 to T9) to subdivide the poly(A)1 RNA popu-
lation. The subdivided cDNA populations were amplified by PCR in the pres-
ence of 10-nucleotide arbitrary primers (AP1 to AP10) by using the Delta RNA
Fingerprinting Kit (Clontech, Palo Alto, Calif.). From PCR experiments with 90
different primer combinations, an average of 6,300 amplified PCR bands were
visualized for each mRNA preparation. Differentially displayed PCR bands were
eluted and amplified by a second round of PCR and then used as probes in
groups of three for Northern analysis. For PCR bands that yielded hybridization
signals with different intensities for wild-type and mutant mRNAs, we cloned the
PCR fragments into a pGEM-T Easy vector (Promega). We then repeated the
Northern blot analysis with individual clones as the probes for genes differentially
expressed in strains carrying the Mediator mutations. For those clones identified
as positive by this procedure, we determined the nucleotide sequences.
RNA preparation and analysis. Cells were grown in YPD medium to early
exponential phase at 30°C, collected by centrifugation, washed with water, and
resuspended with an equal volume of prewarmed (37°C) synthetic complex
medium lacking lysine (for amino acid starvation) or YP-galactose medium (for
galactose induction). After the medium shift, cells were allowed to grow for
additional 2.5 h at 37°C, after which mRNA was prepared as described previously
(24). In order to prepare the probes for Northern analysis, DNA fragments for
the HIS4 gene (from bp 1605 to 11804) and the MFa1 gene (from bp 13 to
1498) were generated by PCR amplification with appropriate primers, and their
sequences were verified by nucleic acid sequencing. For generation of a GAL1
probe, an oligonucleotide complementary to the GAL1 coding region (24) was
synthesized and end labeled with T4 polynucleotide kinase and [g-32P]ATP.
Specifically hybridized signals were quantitated with the use of a PhosphorIm-
ager (Molecular Dynamics, Sunnyvale, Calif.) and the associated software. When
necessary, the filter was stripped by incubation in a 0.1% SDS solution for 10 min
at 90°C and rehybridized with different probes.
RESULTS
Cloning of MED9, MED10, and MED11. The enormous size
of the Mediator complex and its intrinsic binding affinity for
many transcription factors have made it difficult to define its
precise composition. This ambiguity hindered identification of
the Mediator proteins required specifically for the transcrip-
tional activation of distinct groups of genes. Therefore, we pu-
rified the Mediator-Pol II complex (holopolymerase) to homo-
geneity and determined the identities of all of the Mediator
subunits.
We supplemented our earlier fractionation scheme (18) with
an anti-Rgr1 antibody column chromatography to obtain a
highly purified holopolymerase fraction (see Materials and
Methods). The holopolymerase preparation that was eluted
from the anti-Rgr1 antibody column contained no additional
known transcription factors (for example, TAFs, the Swi/Snf
FIG. 1. Polypeptide composition of the Mediator-Pol II complex. (A) SDS-polyacrylamide gel electrophoresis of the holopolymerase complex immunopurified on
an anti-Rgr1 antibody column. Molecular size marker proteins are indicated on the left, and the Pol II and Mediator components, including the new Mediator proteins
(Med9, Med10, and Med11), are indicated on the right. For better resolution of its components, holopolymerase was separated on SDS–7.5% and –13% polyacrylamide
gels, and the boundary of the two protein gels is marked with an asterisk. Med6*, histidine-tagged Med6. (B) Immunoblot analysis of the coimmunoprecipitation of
the Med proteins. The HA-Med10 holopolymerase fraction was immunoprecipitated with an anti-HA monoclonal antibody (12CA5). Equivalent amounts of load (L),
supernatant (S), and pellet (P) from the immunoprecipitation were blotted and probed with the antibodies indicated at the right.
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proteins, and general transcription factors were absent from
the preparation) (Fig. 1A and data not shown). However, we
found a previously unidentified protein band of 20 kDa, which
we named Med9. In addition, we noticed that the Coomassie
blue staining intensities of the 19- and 15-kDa protein bands
(which correspond to Srb7 and Srb6, respectively) were twice
what one would predict for the stoichiometric amount (data
not shown). We named these previously unidentified proteins
of 19 and 15 kDa Med10 and Med11, respectively. The peptide
sequences that we obtained by ion trap mass spectrometry
from the 15-, 19-, and 20-kDa protein bands originated from a
total of five proteins, including Srb6 and Srb7, suggesting that
no additional Mediator proteins were present.
A database search revealed that Med9 is identical to Cse2. A
cse2 mutation (cse2-1) was originally isolated in a genetic
screen for mutations that affect chromosome segregation (42).
However, the role that CSE2 plays in chromosomal segrega-
tion is not known. We also learned that Med10 is identical to
Nut2 (38). A nut2 mutation bypasses the Swi4 requirement
only in the context of a lacZ reporter fused to a minimal HO
promoter. Unlike Med9 and Med10, Med11 is a novel protein
(ORF YMR112C) without sequence similarity to any known
proteins.
The association of these polypeptides with holopolymerase
was confirmed by their cofractionation throughout the holo-
polymerase purification procedure (data not shown). No other
purification fractions contained traceable amounts of the Med
proteins. In order to examine whether Med9, Med10, and
Med11 are all present in a single complex with other Mediator
proteins, Med10 was tagged with an HA epitope, and the
holopolymerase fraction (MonoQ) from the HA-Med10 yeast
strain (YSJ10HA) was immunoprecipitated with an anti-HA
monoclonal antibody (12CA5). Immunoblot and silver staining
analyses showed that Med9, Med11, and other holopolymer-
ase components were immunoprecipitated together with HA-
Med10 (Fig. 1B and data not shown). Immunoprecipitation
with anti-Med9 antibody yielded identical results (data not
shown). Therefore, Med9/Cse2, Med10/Nut2, and Med11 are
genuine components of the Mediator complex.
A search for homologs of these newly identified Mediator
proteins found ORFs similar to that for yeast Med10 in human,
Arabidosis, Caenorhabditis elegans, Schistosoma japonicum, and
Schizosaccharomyces pombe databases. Comparison of yeast
Med10 with other Med10 homologs revealed 50 to 35% se-
quence similarity (24 to 17% identity) (Fig. 2). Recently, hu-
man Med10 was identified independently as a component of a
Mediator component (Srb7, Med6, and Rgr1)-containing hu-
man complex that exhibits both coactivator and repressor
functions in vitro (34, 36). Whether this human complex is
functionally equivalent to the yeast Mediator is not proven yet,
but the identification of multiple human homologs in a com-
plex suggests that at least some of the regulatory function of
Mediator is conserved throughout evolution.
Isolation of med9, med10, and med11 mutants. To conduct
further studies on the newly discovered Mediator proteins, we
generated mutant forms of each of the encoding genes. Be-
cause med9/cse2 was dispensable for cell viability (42), we de-
leted the whole MED9/CSE2 coding region from a haploid cell
to make a med9/cse2 null strain (YSJ9M). As no such infor-
mation was available for MED10 and MED11, we first exam-
ined whether they were essential for cell viability. We gener-
ated MED10 and MED11 deletions in individual diploid yeast
strains. Tetrad analysis of both deletion strains gave only
two viable spores that did not bear the TRP1 deletion mark-
er, demonstrating that both genes are essential for cell via-
bility (data not shown). Therefore, we isolated ts med10-1
and med11-1 mutants as described in Materials and Methods.
The ts phenotypes were caused by specific mutations in the
corresponding Mediator genes such that introduction of a wild-
type copy of the gene rescued the growth defect at the restric-
tive temperature (Fig. 3). Mutation site analysis revealed three
amino acid changes for both the med10-1 (N2D, L61S, and
L64P) and med11-1 (K7N, V67D, and G107S) alleles.
Identification of genes affected by each Mediator mutation.
In order to identify the gene-specific functions of the newly
identified Mediator proteins, we searched for genes whose
expression was affected specifically by individual Mediator mu-
tations. Differential display analyses of mRNA preparations
from wild-type and Mediator mutant strains (see Materials and
Methods) revealed that 37, 19, and 31 RNA fragments were
preferentially amplified from wild-type mRNA compared with
amplified med9, med10, and med11 mutant mRNAs, respec-
tively. Northern blot analysis with the differentially displayed
fragments as probes revealed a total of five transcripts (two for
med9, three for med10, but none for med11) that were reduced
at least fivefold in the mutant strains (Fig. 4). We also found 50
RNA fragments that were amplified only from the mutant
mRNA preparations, but none of them showed more than a
twofold difference in expression between wild-type and mutant
strains (data not shown).
Two genes, ARG4 and YGR260W, were identified as targets
of Med9 regulation. YGR260W encodes a protein that is ho-
mologous to allantotate permease (DAL5). The ARG4 and
YGR260W transcripts were reduced 8- and 10-fold in the med9
mutant, respectively (Fig. 4), and these transcriptional defects
were rescued by introducing a wild-type copy of MED9 (data
not shown). We also examined whether the med9 mutant
strain was defective for transcription of genes involved in chro-
mosomal segregation; however, transcription of a number
of functionally related genes, including MIF2 (3), YMR092C
and YNR047W (14), YLR457C and CBF1 (27), CHL4 (20), and
CIN1 (13), was not compromised by the med9 mutation (data
not shown). Expression of SCM2, the tryptophan permease
gene, which was identified as a high-copy suppressor of the
cold sensitivity phenotype of cse2-1 (5), also was not altered in
the med9 mutant. These results indicate that Med9/Cse2 reg-
ulates the expression of genes involved in amino acid biosyn-
thesis and that the med9 mutant phenotype may result from
compromised amino acid synthesis.
Differential display experiments for the med10 mutant
mRNA preparation also identified three differentially ex-
pressed genes, two amino acid biosynthetic genes (HIS4 and
LYS20) and a novel gene (YGL117W). HIS4, LYS20, and
YGL117W transcripts were specifically reduced 5- to 10-fold by
the defective med10 activity (Fig. 4). Because both the med9
and med10 mutants showed defects in the transcription of genes
involved in amino acid biosynthesis, we examined whether
MED9 and MED10 have common transcriptional regulation
targets. Indeed, the levels of ARG4 and YGR260W transcripts
were reduced 5- and 10-fold in the med10 mutant, respectively
(Fig. 4). Similarly, the med9 mutant was also defective (a three-
to eightfold reduction) in the transcription of the genes af-
fected by the med10 mutation (Fig. 4). These results revealed
that both Med9/Cse2 and Med10 are required for the regula-
tion of certain amino acid biosynthetic genes.
Gene-specific transcriptional regulatory functions of indi-
vidual Mediator genes. Despite the well-documented require-
ment for Mediator genes (for example, MED6, GAL11, SIN4,
HRS1, and RGR1) in the transcriptional activation of genes
involved in carbon source metabolism and mating type speci-
fication (2, 21, 32), the genes identified as regulatory targets of
Med9 and Med10 are involved mostly in amino acid biosyn-
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thesis. This result suggests that different sets of Mediator pro-
teins may function in distinct transcriptional regulation path-
ways. In order to test this hypothesis, we compared the effects
of the transcriptional defects of Mediator mutants (med9 null,
med10 ts, med11 ts, gal11 null, and med6 ts) on transcription of
the GAL1, MFa1, and HIS4 genes, which are regulated spe-
cifically by distinct groups of gene-specific transcriptional ac-
tivator proteins (Fig. 5). Transcription of GAL1 and MFa1 is
regulated by Gal4 and Mcm1/Mata1, respectively, whereas
regulation of HIS4 transcription requires the concerted partic-
ipation of Bas1/Bas2, Rap1, and Gcn4 (6). In an amino acid-
rich environment, Bas1/Bas2 and Gcn4 are required indepen-
dently for the basal expression of HIS4, and Rap1 augments
DNA binding by Bas1/Bas2 and Gcn4 (6). Upon amino acid
starvation, Gcn4 is overproduced by a translational control
mechanism and drives Gcn4-mediated transcriptional activa-
tion (10).
Northern analysis revealed that the med9 and med11 muta-
tions reduced specifically basal transcription of HIS4 (an 8-fold
reduction) and activated transcription of MFa1 (a 2.3-fold re-
duction), respectively (Fig. 5, MED9 and MED11). The med10
mutation had no effect on GAL1 transcription but reduced the
levels of activated MFa1 transcription (9-fold), as well as basal
(5-fold) and activated (15-fold) HIS4 transcription (Fig. 5,
MED10). As shown previously (8, 24, 31), the gal11 null and
med6 ts mutations diminished severely transcription of GAL1
and MFa1. However, these mutations affected HIS4 transcrip-
tion in distinct ways. Both basal and activated HIS4 transcrip-
tion were decreased slightly in the gal11 mutant but were
diminished severely in the med6 ts mutant (Fig. 5, GAL11 and
MED6). Taken together, these results reveal several interesting
phenomena. First, each Mediator mutant exhibited a distinct
transcriptional defect pattern. Even the med9 and med10 mu-
tants had completely different effects on HIS4 transcription
under amino acid starvation conditions. Second, the fact that
Med6 is absolutely required for most of the transcriptional
FIG. 2. Sequence alignment of Med10 homologs. Protein sequences of Med10 homologs from S. cerevisiae (GenBank accession no. U25840), S. pombe (2226420),
C. elegans (1176601), S. japonicum (AA661070), Arabidopsis thaliana (AA042215), and human (AA429956) are aligned. Identical amino acids (black boxes), similar
amino acids (shaded boxes), and gaps in the sequence (dashed line) are indicated.
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activation events tested suggests that Med6 may function down-
stream of the other Mediator proteins to modulate Pol II ac-
tivity.
Activator specificity of Mediator proteins. The observation
of distinct transcriptional defects for individual Mediator mu-
tants suggests that each gene-specific transcriptional activator
protein requires a certain Mediator protein(s) to accomplish
the transcriptional activation of a particular gene. Specifically,
the distinct requirements for Med9, Med10, and Gal11 in the
different types of HIS4 transcriptional regulation suggest that
each of these Mediator proteins may interact with one of the
three HIS4 transcriptional activators, Bas1/Bas2, Gcn4, and
Rap1. Because Gal11 has been suggested to interact with
Rap1, we examined the effects of the med9, med10, and gal11
mutations on transcriptional activation of ARG4, which con-
tains only the Bas1/Bas2 and Gcn4 binding sites without the
Rap1 binding site. The transcriptional defects of ARG4 in
med9 and med10 mutants were identical to those of HIS4
in the same mutants. However, ARG4 transcription was not
compromised in the gal11 mutant (data not shown), con-
firming that Gal11 mediates transcriptional stimulation by
Rap1.
In order to demonstrate that the distinct requirements for
Med9 and Med10 in HIS4 transcription resulted from their
specific interaction with the Bas1/Bas2 and Gcn4 activators, we
used lacZ reporter plasmids bearing either a Gcn4 binding site
or multiple LexA binding sites upstream of the CYC1 core
promoter. We cotransformed the LexA-driven reporter con-
struct and a multicopy LexA-Bas2 expression construct (43)
into wild-type and Mediator mutant strains and examined the
levels of lacZ expression at the nonpermissive temperature.
Bas2-mediated transcriptional activation was abolished com-
pletely in the med9 mutant (a 170-fold reduction) and dimin-
ished in the med10 mutant (a 7.5-fold reduction) (Fig. 6). On
the other hand, transcriptional activation of the lacZ reporter
gene containing the Gcn4 binding site was severely defective
only in the med10 mutant when cells were grown under amino
acid starvation conditions at the nonpermissive temperature
(Fig. 6) (a 10-fold reduction). These results demonstrate that
Med9 is required specifically for Bas2-mediated transcriptional
activation, whereas Med10 is required for Bas2- and Gcn4-
mediated transcriptional activation.
In vitro transcription of mutant holopolymerase. The in vivo
analysis described above showed that specific activator pro-
teins require a distinct Mediator protein(s) to regulate the Pol
II transcription machinery. In order to examine whether the
activator-specific properties of Mediator are present in the
absence of additional cofactors, we examined the effects of
Mediator mutations on basal and activated transcription in a
defined in vitro transcription system reconstituted with pure
basal transcription factors, activator protein, and holopolymer-
ase.
When equivalent amounts (based on nonspecific polymerase
activities) of the wild-type and med9 null holopolymerases
were tested for basal transcription, the wild-type holopolymer-
ase displayed an eightfold-higher level of basal transcription
than did the med9 null holopolymerase (Fig. 7A, lanes 1 to 3
versus lanes 4 to 6). Even when equivalent amounts of Medi-FIG. 3. ts phenotypes of the newly identified Mediator mutants. Yeast strainswere spotted in duplicate on YPD agar plates, and each plate was incubated for
3 days at either the permissive (30°C) or nonpermissive (37°C) temperature. The
temperature sensitivities of the wild-type strains (W), Mediator mutant strains
(M), and mutant strains transformed with the corresponding wild-type Mediator
gene (rescued [R]) were compared for med9 null (A), med10 ts (B), and med11
ts (C) mutants. At the bottom of each panel, the type of mutations and the
mutated amino acids and their positions are shown.
FIG. 4. Northern analysis of genes isolated from differential display of Me-
diator mutant mRNAs. Wild-type (W) and mutant (M) mRNAs for each of the
Mediator genes indicated at the top were prepared from yeast cells grown in
YPD at the nonpermissive temperature. Each mRNA blot was hybridized with
the probe indicated at the left. As an RNA loading control, actin transcript levels
are shown.
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ator proteins were present, the med9 mutant holopolymerase
displayed about 50% of the level of basal transcription activity
shown by the wild-type holopolymerase (Fig. 7A, lanes 7 to 9).
However, upon addition of the activators Gal4VP16 and Gcn4,
both the wild-type (20- to 27-fold activation) and med9 mutant
(20- to 28-fold activation) holopolymerases were able to acti-
vate transcription from specific enhancer-containing tem-
plates (Fig. 7A). This result indicates that Med9 is not re-
quired for Gal4VP16- and Gcn4-mediated transcriptional
activation.
In contrast, when equal amounts of wild-type, med10 ts, and
med11 ts mutant holopolymerases were tested in vitro, an
equivalent level of basal and activated (25- to 30-fold) tran-
scription was observed at the permissive temperature (Fig. 7B,
lanes 1 to 9). However, under nonpermissive conditions, the
med10 mutant holopolymerase was defective for activated
transcription (Fig. 7B, lanes 13 to 15). Although heat treat-
ment reduced significantly the basal activities of the holopoly-
merases, small amounts of transcripts were detected in the
transcription reactions of both wild-type and mutant holopoly-
merases. However, the robust transcriptional activation of the
med10 ts holopolymerase observed under permissive condi-
tions was abolished completely under nonpermissive condi-
tions (Fig. 7B, lanes 5 and 6 versus lanes 14 and 15). Therefore,
mediation of the transcriptional activator signals to Pol II was
inhibited specifically in the med10 mutant. The fact that both
the in vivo and in vitro transcription assays displayed similar
defects suggests that Med10 is needed for direct regulation of
FIG. 5. Activator-specific transcriptional defects of Mediator mutants. Poly(A)1 RNA was isolated from wild-type strains (W), mutant strains (M), and mutant
strains transformed with the corresponding wild-type Mediator gene (rescued [R]) for each of the Mediator mutants (MED9, MED10, MED11, GAL11, and MED6)
noted at the top. In order to measure the levels of the transcripts indicated at the left, cells were grown under galactose induction (GAL1), amino acid-rich conditions
(HIS4 B), or amino acid starvation conditions (HIS4 A). All of the yeast cells used in this experiment are a mating type cells and thus display activated MFa1
transcription (MFa1). The levels of MFa1 transcripts in the med9 and med11 mutant strains containing then wild-type Mediator genes (MED9 R and MED11 R) and
in the gal11 mutant strain (GAL11 W and M) were not determined. Each blot was hybridized with the probes indicated at the left. For each Northern blot, the level
of actin mRNA was measured as an RNA loading control, and a typical result is shown.
FIG. 6. Activator-specific requirement for Med9 and Med10. The structures of the lacZ reporter constructs containing a binding site(s) for one activator type are
shown along with the transcriptional activator used for the assay. The b-galactosidase activities from the averages of two triplicate assays are shown with standard
deviations (SD). The strains used were YPHBAS (wild type1), YSJ9BAS med9 null (med91), and YSJ10BAS med10 ts (med101) for the Bas2 assay, while YPHG4 (wild
type2), YSJ9G4 med9 null (med92), and YSJ10G4 med10 ts (med102) were used for the Gcn4 assay.
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holopolymerase by specific activator proteins. However, wheth-
er Gcn4 and Gal4VP16 utilize identical activation mechanisms
or require additional cofactors for activator specificity in vivo is
not yet known.
DISCUSSION
Activator-specific subunits of Mediator. The modular orga-
nization of Mediator was first suggested by the identification of
the Gal11 module (26). Subsequently, differential salt dissoci-
ation experiments (23) and partial reconstitution of the Srb4
Mediator subcomplex with recombinant proteins (19) revealed
the presence of the Rgr1 and Srb4 subcomplexes, which appear
to function at each end of the signal transfer between tran-
scriptional activators and Pol II (23). Recently, we found that
acidic activators bind strongly to the Gal11 protein of the Rgr1
subcomplex, demonstrating that the Gal11 module is an acti-
vator binding target (25). However, the gal11 mutation exerts
its effect on the transcription of only a limited number of genes
(8, 31). This observation suggests that multiple modules or
individual Mediator proteins with different activator specifici-
ties exist in the Mediator complex. Other Mediator compo-
nents associated with Rgr1 are candidates for such a role, but
genetic evidence for these putative functional interactions was
FIG. 7. In vitro transcription activities of Mediator mutant holopolymerases. In vitro transcription reactions were reconstituted as described by Lee et al. (24).
Activators (Gal4VP16 [30 ng] and Gcn4 [30 ng]) were added to the reaction mixtures as indicated. The reaction mixtures were incubated on ice (A) or at the indicated
temperature (B) for 10 min for initiation complex formation, and then [a-32P]UTP (10 mCi) and 0.5 mM CTP were added and the reaction mixtures were incubated
further at 25°C for 30 min. Specifically initiated transcripts from a template containing either a Gcn4 binding site (GCN4:G-) or a Gal4 binding site (GAL:G-) are
indicated. (A) Transcriptional activity of wild-type holopolymerase (lanes 1 to 3) and equivalent amounts of med9 null holopolymerase based on nonspecific RNA
polymerase activity (lanes 4 to 6) or based on Mediator content (lanes 7 to 9). (B) Transcriptional activity of wild-type (lanes 1 to 3 and 10 to 12), med10 ts (lanes 4
to 6 and 13 to 15), and med11 ts (lanes 7 to 9 and 16 to 18) holopolymerases under permissive (25°C, lanes 1 to 9) or restrictive (37°C, lanes 10 to 18) conditions.
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heretofore unavailable. Therefore, the identification of the ac-
tivator-specific requirements of Med9, Med10, and Med11
supports the hypothesis that the Mediator complex consists of
multiple activator-specific components.
It should be noted that the Med6 protein in the Srb4 sub-
complex is required for the transcriptional activation of a
broader range of genes than are the other Med proteins in the
Rgr1 subcomplex. The med6 mutation caused defects in the
transcriptional activation of all genes whose transcription is
dependent on other specific Mediator proteins. This result
suggests that transcriptional activation signals targeted to a
specific subunit(s) of Mediator complex may all converge on
Med6 during the regulatory process. Med6 may then, in turn,
relay the signals to Pol II via the Srb proteins. The general
requirement of Srb4 for Pol II transcription suggests that Srb4
functions in the enhancement of basal transcription by Pol II
rather than in the mediation of gene-specific activator signals.
However, a weak binding affinity between Srb4 and gene-spe-
cific transcriptional activators was detected in an in vitro bio-
chemical assay (19). Determination of whether Srb4 consti-
tutes a major target of transcriptional activators in vivo and
forms an additional activator-specific module is left for more
rigorous examinations.
Activator specificity of the Mediator modules. Our results
show that deletion of the med9 gene caused a specific defect in
Bas1/Bas2-dependent basal HIS4 transcription, while a med10
mutation yielded defects in Gcn4-dependent basal and acti-
vated transcription of HIS4. Neither of these mutations had an
effect on the transcription of GAL1, which is regulated by the
Gal4 protein. Genetic mutations in Gal11 module components
cause severe transcriptional defects of Gal4-dependent genes.
Thus, the Med9, Med10, and Gal11 modules appear to me-
diate transcriptional regulatory signals from the Bas1/Bas2,
Gcn4, and Gal4 transcriptional activators, respectively (Fig. 8).
Although Gal4 is not implicated in HIS4 transcription, the
level of HIS4 transcription in wild-type yeast strains is two- to
threefold higher than that in strains that carry a defective
Gal11 module component (gal11 or sin4) (16, 31). However,
the transcriptional defects of gal11 and sin4 mutants appear to
be related to Rap1 rather than to Bas1/Bas2 or Gcn4. Rap1
binds to the HIS4 promoter and stimulates both Bas1/Bas2-
and Gcn4-dependent HIS4 transcription two- to threefold, es-
pecially under uninduced conditions (6). Although a direct
interaction between the Gal11 module and Rap1 has not been
established, sin4 and gal11 mutants have been shown to be
defective in the transcription of genes that contain a Rap1
binding site in their promoters (for example, HIS4, PYK1,
CTS1, MATa, and Ty1) (16, 31). Genes whose transcription is
controlled by Bas1/Bas2 and Gcn4 but which do not have a
Rap1 binding site in their promoters (for example, the purine
biosynthetic genes and HIS3) are not affected by sin4 or gal11
mutations. In particular, ARG4, which does not have a Rap1
binding site, displays a transcriptional requirement for Med9
and Med10 identical to that of HIS4. However, unlike HIS4,
ARG4 does not require the Gal11 module for full-level tran-
scription (data not shown). These observations are consistent
with the notion that each Mediator module has a distinct
activator specificity.
Future directions. The identification of the entire comple-
ment of Mediator proteins and their functional analyses pre-
sented here address one of the major questions with respect to
transcriptional activation mechanisms: how is the activator-
specific property of Mediator achieved? In addition to the
Gal11 module, which is required for Gal4-mediated transcrip-
tional activation, the identification of Med9, Med10, and
Med11, which are required for the transcription of distinct
groups of genes, clearly demonstrates the existence of activa-
tor-specific Mediator pathways. In addition, a group of Medi-
ator subunits, including Rgr1, Sin4, and Gal11, is involved in
transcriptional repression as well as activation (8, 15, 16). The
observation that the various Mediator functions (activation,
FIG. 8. A model for activator-specific modules of Mediator complex. Three
models for activator-specific interactions of the Mediator complex are shown.
Filled and linear arrows indicate the specific functional interactions revealed by
in vivo transcription assays. Shaded arrows represent transcription initiation. (A)
Galactose induction conditions. Gal4 bound to the enhancer interacts with the
Gal11 module of Mediator, which induces Pol II and the general transcription
factors (GTFs) to transcribe GAL1 at higher efficiency. (B) Amino acid-rich
conditions. Med9 and Med10 mediate specifically basal-level HIS4 transcription
via Bas1/Bas2 and Gcn4, respectively. Stimulation of Bas1/Bas2- and Gcn4-
dependent transcription by Rap1 through the Gal11 module is indicated by a
linear arrow. The putative requirement for Med10 in Bas2-mediated transcrip-
tion is indicated by a dotted arrow. (C) Amino acid starvation conditions. The
major transcriptional activation of HIS4 by the specific interaction of (overpro-
duced) Gcn4 protein with Med10 is shown as a filled arrow, compared to the
relatively minor contribution from Rap1 to the Gcn4-mediated transcriptional
activation via the Gal11 module (linear arrow).
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repression, and stimulated basal transcription) require differ-
ent sets of Mediator proteins further supports the notion of
multiple functional modules of the Mediator complex. The
reconstitution of activator- or repressor-specific Mediator
modules with recombinant proteins in vitro should provide a
complete biochemical description of the molecular interac-
tions among transcriptional activators and Mediator compo-
nents.
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